DDX5 and colorectal cancer: Clinical studies have also found that higher levels of O‐GlcNAcylation are involved in the malignant clinicopathological features of various cancer patients.12, 18, 33, 34 In gastric carcinoma, poorly differentiated tumours (grades II and III) showed significantly higher expression of O‐GlcNAcylation than grade I tumours.35, 36 At the same time, we detected the expression of O‐GlcNAcylation and DDX5 in colorectal cancer tissues and matched normal controls.